214 related articles for article (PubMed ID: 19010710)
1. Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease.
Lunardi G; Galati S; Tropepi D; Moschella V; Brusa L; Pierantozzi M; Stefani A; Rossi S; Fornai F; Fedele E; Stanzione P; Hainsworth AH; Pisani A
Parkinsonism Relat Disord; 2009 Jun; 15(5):383-9. PubMed ID: 19010710
[TBL] [Abstract][Full Text] [Related]
2. Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease.
Poceta JS; Parsons L; Engelland S; Kripke DF
Sleep Med; 2009 Jan; 10(1):129-33. PubMed ID: 18207455
[TBL] [Abstract][Full Text] [Related]
3. Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system.
González-Quevedo A; García JC; Fernández R; Fernández Cartaya L
Bol Estud Med Biol; 1993; 41(1-4):13-9. PubMed ID: 7521168
[TBL] [Abstract][Full Text] [Related]
4. Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment.
Stefani A; Pierantozzi M; Olivola E; Galati S; Cerroni R; D'Angelo V; Hainsworth AH; Saviozzi V; Fedele E; Liguori C
Neurochem Int; 2017 May; 105():58-63. PubMed ID: 28108196
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
[TBL] [Abstract][Full Text] [Related]
6. Visual and auditory evoked potentials in early onset Parkinson's disease and their relationship to cerebrospinal fluid monoamine metabolites.
Muthane UB; Satishchandra P; Subhash MN
Mov Disord; 1993 Jul; 8(3):344-8. PubMed ID: 7688076
[TBL] [Abstract][Full Text] [Related]
7. Biochemical aids in the diagnosis of Parkinson's disease.
Chase TN; Eng N; Gordon EK
Ann Clin Lab Sci; 1976; 6(1):4-10. PubMed ID: 1247283
[TBL] [Abstract][Full Text] [Related]
8. 14C-homovanillic acid in the cerebrospinal fluid of parkinsonian patients after intravenous 14C-L-dopa.
Extein I; Van Woert M; Roth RH; Bowers MB
Biol Psychiatry; 1976 Apr; 11(2):227-32. PubMed ID: 971447
[TBL] [Abstract][Full Text] [Related]
9. Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease.
Cheng FC; Kuo JS; Chia LG; Dryhurst G
J Neural Transm (Vienna); 1996; 103(4):433-46. PubMed ID: 9617787
[TBL] [Abstract][Full Text] [Related]
10. Markers of dopamine depletion and compensatory response in striatum and cerebrospinal fluid.
Loeffler DA; LeWitt PA; DeMaggio AJ; Juneau PL; Milbury PE; Matson WR
J Neural Transm Park Dis Dement Sect; 1995; 9(1):45-53. PubMed ID: 7605589
[TBL] [Abstract][Full Text] [Related]
11. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study.
Sossi V; de la Fuente-Fernández R; Schulzer M; Troiano AR; Ruth TJ; Stoessl AJ
Ann Neurol; 2007 Nov; 62(5):468-74. PubMed ID: 17886297
[TBL] [Abstract][Full Text] [Related]
12. Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off.
Rajput AH; Fenton ME; Di Paolo T; Sitte H; Pifl C; Hornykiewicz O
Parkinsonism Relat Disord; 2004 Jun; 10(4):221-6. PubMed ID: 15120096
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study.
Zubenko GS; Marquis JK; Volicer L; Direnfeld LK; Langlais PJ; Nixon RA
Biol Psychiatry; 1986 Dec; 21(14):1365-81. PubMed ID: 3024746
[TBL] [Abstract][Full Text] [Related]
14. Opposite changes in dopamine metabolites and met-enkephalin levels in the ventricular CSF of patients subjected to thalamic electrical stimulation.
Bourgoin S; Rostaing-Rigattieri S; Nguyen JP; Berberich E; Duvaldestin P; Fattaccini CM; Hamon M; Cesselin F
Clin Neuropharmacol; 1999; 22(4):231-8. PubMed ID: 10442254
[TBL] [Abstract][Full Text] [Related]
15. Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.
Goldstein DS; Holmes C; Sullivan P; Jinsmaa Y; Kopin IJ; Sharabi Y
Parkinsonism Relat Disord; 2016 Oct; 31():79-86. PubMed ID: 27474472
[TBL] [Abstract][Full Text] [Related]
16. Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans.
Przedborski S; Levivier M; Raftopoulos C; Naini AB; Hildebrand J
Mov Disord; 1995 Jan; 10(1):28-36. PubMed ID: 7885353
[TBL] [Abstract][Full Text] [Related]
17. A study of CSF catecholamine and its metabolites in acute and convalescent period of encephalitis.
Kalita J; Kumar S; Vijaykumar K; Palit G; Misra UK
J Neurol Sci; 2007 Jan; 252(1):62-6. PubMed ID: 17134724
[TBL] [Abstract][Full Text] [Related]
18. Adh1 and Adh1/4 knockout mice as possible rodent models for presymptomatic Parkinson's disease.
Anvret A; Ran C; Westerlund M; Gellhaar S; Lindqvist E; Pernold K; Lundströmer K; Duester G; Felder MR; Galter D; Belin AC
Behav Brain Res; 2012 Feb; 227(1):252-7. PubMed ID: 22079585
[TBL] [Abstract][Full Text] [Related]
19. [Study on dopamine metabolite in cerebrospinal fluid of schizophrenics and epilepsics].
Jiang S; Chen X; Liao W
Hunan Yi Ke Da Xue Xue Bao; 1998; 23(2):155-6. PubMed ID: 10681831
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid homovanillic acid and parkinsonism in Huntington's disease.
Kurlan R; Goldblatt D; Zaczek R; Jeffries K; Irvine C; Coyle J; Shoulson I
Ann Neurol; 1988 Aug; 24(2):282-4. PubMed ID: 2972251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
